Economic Burden of Sickle Cell Disease: A Retrospective Study of Pediatric and Adult Individuals With Medicaid Coverage From 2016 to 2020
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70146 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Giovanna Tedesco Barcelos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer AG, Zürich, Switzerland. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Medicaid, Cost of Illness, Health Care Costs. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
There is limited information regarding the contemporary real‐world clinical and financial burden of Medicaid enrollees with sickle cell disease (SCD) in the United States. Using the IBM MarketScan Medicaid database (7/2016–12/2020), individuals with ≥ 3 SCD diagnoses were matched 1:1 on age, gender, and race to individuals without SCD. Continuous coverage was required during 6‐month baseline and 12‐month follow‐up periods. Follow‐up healthcare resource utilization (HCRU) and costs were compared between the SCD and non‐SCD cohorts in separate analyses of the pediatric (< 18 years, n = 4723 per cohort, 52% male, mean age: 8.8 years) and adult (≥ 18 years, n = 5597 per cohort, 60% female, mean age: 35.1 years) populations. During follow‐up, pediatric individuals with SCD had significantly more hospitalizations (0.8 vs. 0.03) with longer length of stay (LOS, 3.0 vs. 0.1 days), outpatient visits (19.5 vs. 10.8), prescriptions (12.8 vs. 3.8), and higher mean total costs ($18 900 vs. $2127) than individuals without SCD; hospitalizations (39.6‐fold) and pharmacy use (11.9‐fold) accounted for the largest cost differences. Adults with SCD had significantly more hospitalizations (2.1 vs. 0.1; LOS: 11.3 vs. 0.7 days), outpatient visits (46.5 vs. 22.5), office visits (7.7 vs. 4.9), prescriptions (29.5 vs. 13.7), and higher mean total costs ($45 114 vs. $6039) than adults without SCD; hospitalizations (18.7‐fold) and ER visits (12.7‐fold) had the greatest cost differences. In conclusion, pediatric and adult Medicaid enrollees with SCD had significantly higher HCRU and costs, demonstrating an unmet need for improved management of SCD to potentially reduce the economic burden for both payers and individuals with SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pfizer AG, Zürich, Switzerland.
- Pfizer Portugal, Porto Salvo, Portugal.
- Pfizer Inc, New York, New York, USA.
- Novosys Health, Miami, Florida, USA.
ORCID-Profile: Giovanna Tedesco Barcelos
Förderung
- Pfizer
Zitieren
APA
Barcelos, G. T., Peixoto, T., Alvir, J., Lin, J., & Baker, C. L. (2026). Economic Burden of Sickle Cell Disease: A Retrospective Study of Pediatric and Adult Individuals With Medicaid Coverage From 2016 to 2020. American Journal of Hematology. https://doi.org/10.1002/ajh.70146
Vancouver
Barcelos GT, Peixoto T, Alvir J, Lin J, Baker CL. Economic Burden of Sickle Cell Disease: A Retrospective Study of Pediatric and Adult Individuals With Medicaid Coverage From 2016 to 2020. American Journal of Hematology. 2026. doi:10.1002/ajh.70146
BibTeX
@article{Barcelos2026,
author = {Barcelos, Giovanna Tedesco and Peixoto, Telma and Alvir, Jose and Lin, Jay and Baker, Christine L},
title = {Economic Burden of Sickle Cell Disease: A Retrospective Study of Pediatric and Adult Individuals With Medicaid Coverage From 2016 to 2020},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70146}
}
EUVIMED